Navigation Links
Intra-Cellular Therapies Announces Positive Results with ITI-002 in Pre-Clinical Models of Parkinson's Disease
Date:10/1/2010

ge, reaching 4% of the population over 80. Mean age of onset is around 60 years, although in 5-10% of cases the onset is earlier and occurs between the ages of 20 and 50. Primary symptoms include decreased motor function caused by appearance of tremor, rigidity, bradykinesia, and postural instability.  Many patients co-morbidly exhibit impaired cognitive function, depression and excessive day time sleepiness. Dopamine replacement therapies, such as L-DOPA, are the current treatments of choice. However, with time on drug and with disease progression, these drug therapies often lose effectiveness and can cause unwanted side effects such as dyskinesias and hallucinosis.

ABOUT INTRA-CELLULAR THERAPIES

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company developing novel drugs for the treatment of diseases and disorders of the Central Nervous System (CNS).  Building on the science generated from the Nobel Prize winning laboratory of Dr. Paul Greengard at The Rockefeller University, the Company develops compounds that have the potential to treat a wide range of diseases associated with the CNS, including schizophrenia, sleep disorders, Parkinson's disease and Alzheimer's disease, cognitive deficits in schizophrenia, depression and female sexual dysfunction, and other disorders pertaining to Women's Health.  To aid in the development process, ITI incorporates its CNSProfile™, a state-of-the-art platform that allows the Company to choose compounds with the strongest potential to succeed in these difficult to treat diseases.


'/>"/>
SOURCE Intra-Cellular Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
2. Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
3. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
4. Vital Therapies Expands SILVER Trial to Saudi Arabia
5. Prometheus and Tarrot Laboratories Collaborate to Identify Markers Associated With Response to Anti-TNF Therapies in Crohns Disease
6. PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies
7. US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research
8. NeoStem to Receive $700,000 from the U.S. Armys Medical Research and Materiel Command to Advance Adult Stem Cell Therapies in Treating Traumatic Wounds
9. New Cancer Treatments and Combination Therapies Presented by Leading Experts from the John Theurer Cancer Center at the American Society of Clinical Oncology Annual Meeting
10. ALS Therapy Development Institute and Oxford BioMedica Begin Second Phase of Collaboration to Develop Gene Therapies for Amyotrophic Lateral Sclerosis
11. 5th Annual Summit to Feature New Stem Cell Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/26/2014)... 26, 2014 The report "Data ... Network Security Equipment, WAN Optimization Appliances]: Global Advancements, ... the data center networking market into various segments ... The report also identifies the factors driving this ... it along with the future roadmaps. , Browse ...
(Date:10/25/2014)... 25, 2014 The report “Adipic ... by Geography - Global Trends & Forecast to ... respect to market drivers, opportunities, and trends in ... and 27 figures spread through 217 slides and ... Trends & Forecast to 2019”., http://www.marketsandmarkets.com/Market-Reports/adipic-acid-269.html , ...
(Date:10/25/2014)... New York, NY (PRWEB) October 23, 2014 ... today announced the winners for the 2014 BioProcess ... collaborations, business strategies, social corporate responsibility and technology ... better, more effective treatments to a global patient ... recognized by their peers during a very entertaining ...
(Date:10/25/2014)... (PRWEB) October 24, 2014 DuPont ... plans to more than double the acreage contracted ... geographies supplying its soybean crush facility in Salisbury, ... this program will target several markets including foodservice ... with good performance. , For the 2015 growing ...
Breaking Biology Technology:Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 2Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 3Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 4Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 2Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 3Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 2BioProcess International Announces Winners of the 2014 BioProcess International Awards 3BioProcess International Announces Winners of the 2014 BioProcess International Awards 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 5DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 2DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 3DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 4
... Family of, Tissue Dissection Tools, Which Have Been Used ... ... Calif., Oct. 28 PEAK Surgical, Inc., a,medical device company ... proprietary technology, has introduced two extensions to its,PEAK PlasmaBlade(TM) family ...
... Senomyx,s Discovery of a Promising New Flavor Ingredient Achieves ... Collaboration ... (Nasdaq: SNMX ), a leading company focused on using proprietary,technologies ... ingredient supply industries, announced today that it has,received a payment from ...
... to Advance P-552, DURHAM, N.C., Oct. 28 ... they have entered into an agreement to,co-develop Parion,s proprietary ... mouth associated with primary Sjogren,s syndrome., Under the ... P-552. Kainos will provide funding to help advance the,program ...
Cached Biology Technology:PEAK Surgical Introduces PlasmaBlade(TM) Product Line Extensions for Use in General Surgery 2PEAK Surgical Introduces PlasmaBlade(TM) Product Line Extensions for Use in General Surgery 3SENOMYX ANNOUNCES RECEIPT OF MILESTONE PAYMENT FROM THE COCA-COLA COMPANY 2SENOMYX ANNOUNCES RECEIPT OF MILESTONE PAYMENT FROM THE COCA-COLA COMPANY 3Parion Sciences and Kainos Medicines Sign Clinical Development Agreement for Novel Dry Mouth Treatment 2Parion Sciences and Kainos Medicines Sign Clinical Development Agreement for Novel Dry Mouth Treatment 3
(Date:10/29/2014)... LANSING, Mich. – As bodies decompose, their types ... the clues they provide could mean the difference ... , Michigan State University is using a more ... help Detroit death-scene investigators examine these changing populations. ... as geographical location of death, gender, race, socioeconomic ...
(Date:10/29/2014)... potential of the Barcode of Life Data Systems ... Biodiversity Data Journal (BDJ) used specimen ... these into a human-readable text developed in manuscript within ... used to study the species distributions of ten Nearctic ... BOLD is originally designed to support the generation and ...
(Date:10/29/2014)... 2014 – Ghrelin is a hormone released by the ... is commonly viewed as a psychoactive substance that primarily ... caloric food. , This knowledge, combined with findings ... ghrelin has the potential to stimulate alcohol craving. , ... humans and found that, as they had anticipated, alcohol ...
Breaking Biology News(10 mins):MSU partners with Detroit to investigate death scenes 2Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Ghrelin stimulates an appetite for drinking alcohol 2
... found a critical piece in the evolutionary puzzle that ... ago. The team, from the School of Biomedical ... into more complex cells and found this crucial step ... thought. Team leader and ARC Federation Fellow ...
... The Translational Genomics Research Institute (TGen) today announced the ... the Van Andel Research Institute (VARI) that will maximize ... TGen expects the agreement to create a robust basic-science-to-translational ... for patient benefit. "We are ...
... are especially reactive to stress are more vulnerable to ... their peers. But a new longitudinal study suggests that ... well when they,re raised in supportive environments. The ... the University of California, San Francisco, and the University ...
Cached Biology News:An answer to another of life's big questions 2TGen finalizes alliance with Van Andel Research Institute 2TGen finalizes alliance with Van Andel Research Institute 3High sensitivity to stress isn't always bad for children 2
odz, odd Oz/ten-m homolog 1 [Source:RefSeq_peptide;Acc:NP_055068] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Rabbit polyclonal to NIRF ( Abpromise for all tested applications). Antigen: Synthetic peptide derived from residues 186-235 of human NIRF. Entrez Gene ID: 115426 Swiss Protein ID: Q96PU...
Rabbit polyclonal to ZNF261 ( Abpromise for all tested applications). entrezGeneID: 9203 SwissProtID: Q14202...
sTNF-receptor I Polyclonal Antibody 100 ug affinity purified rabbit anti-human sTNF-receptor I polyclonal antibody. Performs well in WB/Elisa/Neutralization....
Biology Products: